IONS Ionis Pharmaceuticals Inc

Price (delayed)

$35.86

Market cap

$5.06B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.86

Enterprise value

$5.81B

Ionis Pharmaceuticals is a biotechnology company based in Carlsbad, California that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza , Tegsedi , and ...

Highlights
IONS's quick ratio is down by 31% year-on-year but it is up by 13% since the previous quarter
The company's debt has surged by 62% YoY and by 39% QoQ
The company's equity has shrunk by 58% YoY and by 14% QoQ

Key stats

What are the main financial stats of IONS
Market
Shares outstanding
141.15M
Market cap
$5.06B
Enterprise value
$5.81B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
8.68
Price to sales (P/S)
7.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.44
Earnings
Revenue
$687.72M
EBIT
-$193.48M
EBITDA
-$176.79M
Free cash flow
-$52.77M
Per share
EPS
-$3.86
Free cash flow per share
-$0.37
Book value per share
$4.13
Revenue per share
$4.88
TBVPS
$17.51
Balance sheet
Total assets
$2.5B
Total liabilities
$1.91B
Debt
$1.31B
Equity
$582.67M
Working capital
$1.94B
Liquidity
Debt to equity
2.25
Current ratio
7.62
Quick ratio
7.09
Net debt/EBITDA
-4.22
Margins
EBITDA margin
-25.7%
Gross margin
98.3%
Net margin
-78.8%
Operating margin
-32.6%
Efficiency
Return on assets
-21.2%
Return on equity
-64%
Return on invested capital
-7.2%
Return on capital employed
-8.8%
Return on sales
-28.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IONS stock price

How has the Ionis Pharmaceuticals stock price performed over time
Intraday
-0.94%
1 week
-0.91%
1 month
-9.51%
1 year
-26.37%
YTD
-36.58%
QTD
-10.1%

Financial performance

How have Ionis Pharmaceuticals's revenue and profit performed over time
Revenue
$687.72M
Gross profit
$675.79M
Operating income
-$224.14M
Net income
-$541.96M
Gross margin
98.3%
Net margin
-78.8%
The gross profit is down by 28% year-on-year and by 2.8% since the previous quarter
IONS's revenue is down by 27% YoY and by 2.8% QoQ
The company's net margin fell by 15% QoQ
The operating margin has declined by 14% since the previous quarter

Growth

What is Ionis Pharmaceuticals's growth rate over time

Valuation

What is Ionis Pharmaceuticals stock price valuation
P/E
N/A
P/B
8.68
P/S
7.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.44
Ionis Pharmaceuticals's EPS has decreased by 11% QoQ
The company's equity has shrunk by 58% YoY and by 14% QoQ
The stock's price to book (P/B) is 42% less than its 5-year quarterly average of 15.2
The P/S is 33% less than the 5-year quarterly average of 11.0 and 16% less than the last 4 quarters average of 8.8
IONS's revenue is down by 27% YoY and by 2.8% QoQ

Efficiency

How efficient is Ionis Pharmaceuticals business performance
Ionis Pharmaceuticals's return on sales has decreased by 46% QoQ
Ionis Pharmaceuticals's ROIC has decreased by 44% from the previous quarter
IONS's return on equity is down by 38% since the previous quarter
IONS's return on assets is down by 18% since the previous quarter

Dividends

What is IONS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IONS.

Financial health

How did Ionis Pharmaceuticals financials performed over time
The total assets is 30% greater than the total liabilities
IONS's quick ratio is down by 31% year-on-year but it is up by 13% since the previous quarter
The current ratio has declined by 30% year-on-year but it rose by 13% since the previous quarter
The company's debt is 125% higher than its equity
Ionis Pharmaceuticals's debt to equity has soared by 63% from the previous quarter
The company's debt has surged by 62% YoY and by 39% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.